FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3147565893> ?p ?o ?g. }

• W3147565893 abstract "Abstract Background Non-T-cell depleted haploidentical hematopoietic stem cell transplantation (HaploSCT) is being increasingly used in acute lymphoblastic leukemia (ALL) with improving patient outcomes. We have recently reported that outcomes of adult patients (pts) with ALL in complete remission (CR) receiving HaploSCT are comparable to unrelated donor transplants. We now compared HaploSCT and matched sibling donor (MSD) transplants in pts with ALL. Aim To assess transplantation outcomes of HaploSCT and MSD transplants in pts with ALL in CR. Methods We retrospectively analyzed adult patients (≥ 18 years) with ALL who underwent their first allogeneic stem cell transplantation (alloSCT) in first or second CR between 2012 and 2018, either from a T cell replete Haplo or MSD donor, and whose data were reported to the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Multivariate analysis (MVA) adjusting for differences between the groups was performed using the Cox proportional hazards regression model. Propensity score matching was also performed to reduce confounding effects. Results The analysis comprised 2304 patients: HaploSCT-413; MSD-1891. Median follow-up was 25 months. Median age was 37 (range 18–75) and 38 (18–76) years in HaploSCT and MSD, respectively. HaploSCT patients were transplanted more recently than those transplanted from MSD (2016 vs 2015, p < 0.0001). A higher rate of HaploSCT was in CR2 (33.4% vs 16.7%, p < 0.0001), respectively, and fewer received myeloablative conditioning (68% vs 83.2%, p < 0.0001). Cytomegalovirus (CMV) seropositivity was lower in HaploSCT patients (22% vs 28%, p = 0.01) and donors (27.1% vs 33%, p < 0.02), and a higher proportion of the HaploSCTs were performed using a bone marrow (BM) graft (46.2% vs 18.6%, p < 0.0001). The 2 groups did not differ with regard to gender, Karnofsky performance status score, ALL phenotype, Philadelphia chromosome (Ph) positivity and pre-alloSCT measurable residual disease (MRD). Graft versus host disease (GVHD) prophylaxis was mainly post-transplant cyclophosphamide (PTCy) based (92.7%) in the HaploSCT setting, while it was mostly pharmacologic in the setting of MSD (18.7% received ATG). Cumulative incidence of engraftment at day 60 was higher in MSD transplants compared to HaploSCT (98.7% vs 96.3%, p = 0.001), respectively. Day 180 incidence of acute (a) GVHD II-IV and III-IV was higher in HaploSCT vs. MSD: 36.3% vs 28.9% ( p = 0.002 and 15.2% vs 10.5% ( p = 0.005), respectively. Conversely, the 2-year chronic (c) GVHD and extensive cGVHD were 32% vs 38.8% ( p = 0.009) and 11.9% vs 19.5% ( p = 0.001) in HaploSCT vs MSD, respectively. Main causes of death were leukemia (31.8% vs 45%), infection (33.1% vs 19.7%) and GVHD (16.6% vs 19.7%) for HaploSCT and MSD, respectively. Two-year relapse incidence (RI), non-relapse mortality (NRM), leukemia-free survival (LFS), overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were 26% vs 31.6%, 22.9% vs 13%, 51% vs 55.4%, 58.8% vs 67.4% and 40.6% vs 39% for HaploSCT and MSD, respectively. In the MVA, RI was significantly lower in HaploSCT in comparison with MSD, hazard ratio (HR) = 0.66 (95% CI 0.52–0.83, p = 0.004), while NRM was significantly higher, HR = 1.9 (95% CI 1.43–2.53, p < 0.0001). aGVHD grade II-IV and grade III-IV were higher in HaploSCT than in MSD HR = 1.53 (95% CI 1.23–1.9, p = 0.0002) and HR = 1.54 (95% CI 1.1–2.15, p = 0.011), respectively. Extensive cGVHD was lower in HaploSCT compared with MSD, HR = 0.61 (95% CI 0.43–0.88, p = 0.007), while total cGVHD did not differ significantly, HR = 0.94 (95% CI 0.74–1.18, p = 0.58). LFS, OS and GRFS did not differ significantly between the 2 transplant groups, HR = 0.96 (95% CI 0.81–1.14, p = 0.66); HR = 1.18 (95% CI 0.96–1.43, p = 0.11) and HR = 0.93 (95% CI 0.79–1.09, p = 0.37), respectively. These results were confirmed in a matched-pair analysis. Conclusions Outcomes of adult patients with ALL in CR receiving alloSCT from haploidentical donors are not significantly different from those receiving transplants from MSD in terms of LFS, OS and GRFS." @default.
• W3147565893 created "2021-04-13" @default.
• W3147565893 creator A5006267560 @default.
• W3147565893 creator A5007367389 @default.
• W3147565893 creator A5020996390 @default.
• W3147565893 creator A5030994676 @default.
• W3147565893 creator A5037018787 @default.
• W3147565893 creator A5040417184 @default.
• W3147565893 creator A5042552205 @default.
• W3147565893 creator A5054416217 @default.
• W3147565893 creator A5058571002 @default.
• W3147565893 creator A5058925624 @default.
• W3147565893 creator A5062465840 @default.
• W3147565893 creator A5069596141 @default.
• W3147565893 creator A5070767391 @default.
• W3147565893 creator A5081937285 @default.
• W3147565893 creator A5083504452 @default.
• W3147565893 creator A5088899895 @default.
• W3147565893 creator A5089735033 @default.
• W3147565893 creator A5090852676 @default.
• W3147565893 date "2021-04-01" @default.
• W3147565893 modified "2023-10-18" @default.
• W3147565893 title "Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation" @default.
• W3147565893 cites W1530764705 @default.
• W3147565893 cites W1880265034 @default.
• W3147565893 cites W1890840545 @default.
• W3147565893 cites W1957307825 @default.
• W3147565893 cites W1978164777 @default.
• W3147565893 cites W1989410995 @default.
• W3147565893 cites W2086693026 @default.
• W3147565893 cites W2093298135 @default.
• W3147565893 cites W2116483603 @default.
• W3147565893 cites W2138660125 @default.
• W3147565893 cites W2152197116 @default.
• W3147565893 cites W2166247867 @default.
• W3147565893 cites W2219528388 @default.
• W3147565893 cites W2289642929 @default.
• W3147565893 cites W2337859996 @default.
• W3147565893 cites W2519901822 @default.
• W3147565893 cites W2568866949 @default.
• W3147565893 cites W2575076839 @default.
• W3147565893 cites W2592665339 @default.
• W3147565893 cites W2595261904 @default.
• W3147565893 cites W2617116169 @default.
• W3147565893 cites W2790296924 @default.
• W3147565893 cites W2802999222 @default.
• W3147565893 cites W2803563100 @default.
• W3147565893 cites W2888608452 @default.
• W3147565893 cites W2899217356 @default.
• W3147565893 cites W2911845849 @default.
• W3147565893 cites W2935210822 @default.
• W3147565893 cites W2969271899 @default.
• W3147565893 cites W2971090699 @default.
• W3147565893 cites W3006512787 @default.
• W3147565893 cites W3011659144 @default.
• W3147565893 cites W3013694430 @default.
• W3147565893 cites W3023222964 @default.
• W3147565893 cites W3023466866 @default.
• W3147565893 cites W3025423143 @default.
• W3147565893 cites W3031027201 @default.
• W3147565893 cites W3045586285 @default.
• W3147565893 cites W3119504288 @default.
• W3147565893 doi "https://doi.org/10.1186/s13045-021-01065-7" @default.
• W3147565893 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8017786" @default.
• W3147565893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33794963" @default.
• W3147565893 hasPublicationYear "2021" @default.
• W3147565893 type Work @default.
• W3147565893 sameAs 3147565893 @default.
• W3147565893 citedByCount "40" @default.
• W3147565893 countsByYear W31475658932021 @default.
• W3147565893 countsByYear W31475658932022 @default.
• W3147565893 countsByYear W31475658932023 @default.
• W3147565893 crossrefType "journal-article" @default.
• W3147565893 hasAuthorship W3147565893A5006267560 @default.
• W3147565893 hasAuthorship W3147565893A5007367389 @default.
• W3147565893 hasAuthorship W3147565893A5020996390 @default.
• W3147565893 hasAuthorship W3147565893A5030994676 @default.
• W3147565893 hasAuthorship W3147565893A5037018787 @default.
• W3147565893 hasAuthorship W3147565893A5040417184 @default.
• W3147565893 hasAuthorship W3147565893A5042552205 @default.
• W3147565893 hasAuthorship W3147565893A5054416217 @default.
• W3147565893 hasAuthorship W3147565893A5058571002 @default.
• W3147565893 hasAuthorship W3147565893A5058925624 @default.
• W3147565893 hasAuthorship W3147565893A5062465840 @default.
• W3147565893 hasAuthorship W3147565893A5069596141 @default.
• W3147565893 hasAuthorship W3147565893A5070767391 @default.
• W3147565893 hasAuthorship W3147565893A5081937285 @default.
• W3147565893 hasAuthorship W3147565893A5083504452 @default.
• W3147565893 hasAuthorship W3147565893A5088899895 @default.
• W3147565893 hasAuthorship W3147565893A5089735033 @default.
• W3147565893 hasAuthorship W3147565893A5090852676 @default.
• W3147565893 hasBestOaLocation W31475658931 @default.
• W3147565893 hasConcept C126322002 @default.
• W3147565893 hasConcept C138496976 @default.
• W3147565893 hasConcept C141071460 @default.
• W3147565893 hasConcept C143998085 @default.
• W3147565893 hasConcept C15744967 @default.
• W3147565893 hasConcept C17923572 @default.
• W3147565893 hasConcept C194409129 @default.
• W3147565893 hasConcept C203014093 @default.

• next